Inhibition of Factor XIII Activation by an Anti-Peptide Monoclonal Antibody

Daniela Lukacova, Edgar Haber, Guy L. Reed, Daniela Lukacova, Guy L. Reed, Gary R. Matsueda, Edgar Haber, Gary R. Matsueda

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

As the final enzyme in the coagulation cascade, activated fibrin stabilizing factor or factor XIII catalyzes the intermolecular cross-linking of fibrin chains. To study this enzyme in plasma, we derived a monoclonal antibody (MAb 309) against a peptide sequence (NH2-G-V-N-L-Q-E-F-C-COOH) in the thrombin activation site of factor XIII. Radioimmunoassays indicate that MAb 309 binds specifically to both platelet and plasma factor XIII. Peptide inhibition studies demonstrate that the MAb binds equally well to the factor XIII (FXIII) zymogen and the active form of FXIII (FXIIIa). In immunoblots of whole platelet lysates, MAb 309 binds only to FXIII and does not cross-react with other proteins. In saturation binding studies, the antibody shows a binding avidity of (1.75 ± 0.35) × 109 M-1. MAb 309 also inhibited 99% of apparent FXIIIa activity in a standard transglutaminase assay. SDS-PAGE analysis of fibrin clots showed that MAb 309 inhibited fibrin γ-γ cross-linking. Moreover, MAb 309 accelerated the lysis of plasma clots, consistent with inhibition of fibrin-fibrin and fibrin-α2-antiplasmin cross-linking. Immunoblotting experiments revealed that MAb 309 affected apparent FXIIIa activity by inhibiting the thrombin activation of the FXIII zymogen. In addition to its utility as a specific probe for the FXIII a-subunit, the strategy used to obtain MAb 309 may be used to generate MAbs that inhibit the activation of other coagulation factor zymogens.

Original languageEnglish (US)
Pages (from-to)10164-10170
Number of pages7
JournalBiochemistry
Volume30
Issue number42
DOIs
StatePublished - Oct 1 1991
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry

Fingerprint

Dive into the research topics of 'Inhibition of Factor XIII Activation by an Anti-Peptide Monoclonal Antibody'. Together they form a unique fingerprint.

Cite this